Valtteri Kaasinen1,2,3, Tuomas Kankare2, Juho Joutsa4,2, Tero Vahlberg5. 1. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland valtteri.kaasinen@tyks.fi. 2. Department of Neurology, University of Turku, Turku, Finland. 3. Turku PET Centre, University of Turku, Turku, Finland; and. 4. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland. 5. Department of Clinical Medicine, Biostatistics, University of Turku, Turku, Finland.
Abstract
Multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS) have signs and symptoms overlapping those of Parkinson disease (PD), complicating their clinical diagnosis. Although presynaptic dopaminergic brain imaging with PET and SPECT is clinically widely used for patients with suspected PD, the benefit of functional imaging in atypical parkinsonism syndromes remains unclear. We compared striatal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS, and PD using combined quantitative data from all published studies. Methods: The PubMed database was searched from inception to August 2018 for the terms "dopamine" OR "dopaminergic" AND "PET" OR "SPECT" OR "SPET" and keywords related to PD, MSA, PSP, and CBS. In total, 1,711 publications were identified. PET or SPECT studies comparing patients with atypical parkinsonism to another diagnostic group (PD, MSA, PSP, or CBS) were included. Tracers for dopamine transporter (DAT), aromatic amino acid decarboxylase (AADC), or vesicular monoamine type 2 were investigated. Tracer binding data were extracted from the original articles. Heterogeneity of the data was examined using I 2 statistics, and a random-effects model was used to summarize data. Hedges g was used as an estimator of effect size in group comparisons. Results are reported according to PRISMA guidelines. Results: Thirty-five studies (29 DAT, 6 AADC, no vesicular monoamine type 2 studies) with 356 MSA-P patients, 204 PSP patients, 79 CBS patients, and 62 MSA-C patients were included in the metaanalysis. Caudate nucleus and putamen DAT function was clearly lower in PSP than in PD (caudate: 34.1% difference, g = -1.08, 95% confidence interval [CI] = -1.52 to -0.64; putamen: 18.2%, g = -0.86, 95% CI = -1.50 to -0.21) and MSA-P (striatum: 31.4%, g = -0.70, 95% CI = -1.21 to -0.19) and was clearly lower in MSA-P than in MSA-C (striatum: 46.0%, g = 1.46, 95% CI = 0.23 to 2.68). Although not significant because of limited data, aromatic l-AADC results paralleled the DAT findings. Conclusion: Striatal presynaptic DAT function is clearly lower in PSP patients than in PD and MSA-P patients and is clearly lower in MSA-P patients than in MSA-C patients.
Multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS) have signs and symptoms overlapping those of Parkinson disease (PD), complicating their clinical diagnosis. Although presynaptic dopaminergic brain imaging with PET and SPECT is clinically widely used for patients with suspected PD, the benefit of functional imaging in atypical parkinsonism syndromes remains unclear. We compared striatal presynaptic dopaminergic function in MSA parkinsonism variant (MSA-P), MSA cerebellar variant (MSA-C), PSP, CBS, and PD using combined quantitative data from all published studies. Methods: The PubMed database was searched from inception to August 2018 for the terms "dopamine" OR "dopaminergic" AND "PET" OR "SPECT" OR "SPET" and keywords related to PD, MSA, PSP, and CBS. In total, 1,711 publications were identified. PET or SPECT studies comparing patients with atypical parkinsonism to another diagnostic group (PD, MSA, PSP, or CBS) were included. Tracers for dopamine transporter (DAT), aromatic amino acid decarboxylase (AADC), or vesicular monoamine type 2 were investigated. Tracer binding data were extracted from the original articles. Heterogeneity of the data was examined using I 2 statistics, and a random-effects model was used to summarize data. Hedges g was used as an estimator of effect size in group comparisons. Results are reported according to PRISMA guidelines. Results: Thirty-five studies (29 DAT, 6 AADC, no vesicular monoamine type 2 studies) with 356 MSA-P patients, 204 PSPpatients, 79 CBSpatients, and 62 MSA-C patients were included in the metaanalysis. Caudate nucleus and putamen DAT function was clearly lower in PSP than in PD (caudate: 34.1% difference, g = -1.08, 95% confidence interval [CI] = -1.52 to -0.64; putamen: 18.2%, g = -0.86, 95% CI = -1.50 to -0.21) and MSA-P (striatum: 31.4%, g = -0.70, 95% CI = -1.21 to -0.19) and was clearly lower in MSA-P than in MSA-C (striatum: 46.0%, g = 1.46, 95% CI = 0.23 to 2.68). Although not significant because of limited data, aromatic l-AADC results paralleled the DAT findings. Conclusion: Striatal presynaptic DAT function is clearly lower in PSPpatients than in PD and MSA-P patients and is clearly lower in MSA-P patients than in MSA-C patients.
Authors: Georg Goebel; Klaus Seppi; Eveline Donnemiller; Boris Warwitz; Gregor K Wenning; Irene Virgolini; Werner Poewe; Christoph Scherfler Journal: Eur J Nucl Med Mol Imaging Date: 2010-12-21 Impact factor: 9.236
Authors: Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Gitte M Knudsen; Pierre Malick Koulibaly; Flavio Nobili; Marco Pagani; Osama Sabri; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-16 Impact factor: 9.236
Authors: I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee Journal: Neurology Date: 1996-07 Impact factor: 9.910
Authors: Michael Nocker; Klaus Seppi; Eveline Donnemiller; Irene Virgolini; Gregor K Wenning; Werner Poewe; Christoph Scherfler Journal: Eur J Nucl Med Mol Imaging Date: 2012-03-30 Impact factor: 9.236
Authors: D J Brooks; E P Salmon; C J Mathias; N Quinn; K L Leenders; R Bannister; C D Marsden; R S Frackowiak Journal: Brain Date: 1990-10 Impact factor: 13.501
Authors: Sven Hammesfahr; Christina Antke; Eduards Mamlins; Markus Beu; Lars Wojtecki; Stefano Ferrea; Lars Dinkelbach; Alexia-Sabine Moldovan; Alfons Schnitzler; Hans Wilhelm Müller; Martin Südmeyer Journal: Neurodegener Dis Date: 2016-03-16 Impact factor: 2.977
Authors: Annemarie M M Vlaar; Marinus J P G van Kroonenburgh; Alfons G H Kessels; Wim E J Weber Journal: BMC Neurol Date: 2007-09-01 Impact factor: 2.474
Authors: Susanna Jakobson Mo; Jan Linder; Lars Forsgren; Henrik Holmberg; Anne Larsson; Katrine Riklund Journal: Biomed Res Int Date: 2013-09-19 Impact factor: 3.411
Authors: Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat Journal: Dtsch Arztebl Int Date: 2019-11-01 Impact factor: 5.594
Authors: Elon D Wallert; Elsmarieke van de Giessen; Remco J J Knol; Martijn Beudel; Rob M A de Bie; Jan Booij Journal: J Nucl Med Date: 2022-06 Impact factor: 11.082
Authors: Victor L Villemagne; Frederik Barkhof; Valentina Garibotto; Susan M Landau; Agneta Nordberg; Bart N M van Berckel Journal: Radiology Date: 2021-01-19 Impact factor: 11.105
Authors: Tainá M Marques; Anouke van Rumund; Iris Kersten; Ilona B Bruinsma; Hans J C T Wessels; Jolein Gloerich; Charlotte Kaffa; Rianne A J Esselink; Bastiaan R Bloem; H Bea Kuiperij; Marcel M Verbeek Journal: NPJ Parkinsons Dis Date: 2021-11-30